1. Pink Sheet
  2. >>Geography
  3. >>Europe

GW Pharma's Cannabinoid Medicine Epidyolex Among CHMP Hopefuls

 
• By Vibha Sharma and Maureen Kenny

Seven new medicines, including GW Pharma's orphan cannabidiol product, Epidyolex, are due for an opinion from the European Medicines Agency this week on whether they should be recommended for pan-EU approval.

Leaf_Pills
Decision Time On EU-Wide Approval Of First Plant-Derived Cannabinoid • Source: Shutterstock

Sponsors of seven new medicines, including three orphan drugs, will know by the end of this week whether the European Medicines Agency’s drug evaluation committee, the CHMP, has recommended their products for pan-EU approval.

Among the list of hopefuls is GW Pharmaceutical's orphan cannabidiol product (Epidyolex), for use as an adjunctive therapy for seizures

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Few Takers For EMA’s OPEN Pathway Prompts Rethink

 
• By Vibha Sharma

While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 
• By Eliza Slawther

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.